MedTrace Logo

Understanding the Effect of Metformin on Corus CAD (or ASGES)

NCT02440893 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 37

Last updated 2019-01-31

No results posted yet for this study

Summary

The study goal was to understand the effect of Metformin on Age/Sex/Gene Expression Score (ASGES) or Corus CAD (henceforth "Corus") in pre-diabetic patients who are medication naive. This study provided data to determine if the Corus CAD (ASGES) signature was different in pre-diabetic patients when metformin was newly prescribed and taken.

Conditions

Interventions

DIAGNOSTIC_TEST

Corus CAD (ASGES)

Sponsors & Collaborators

  • CardioDx

    lead INDUSTRY

Principal Investigators

  • Mark Mouton, MD · The Mouton Clinic

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2014-06-30
Completion
2014-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02440893 on ClinicalTrials.gov